A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
Public ClinicalTrials.gov record NCT02214225. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Multicenter, Double-blinded Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (CSL QIV) in Comparison With a US Licensed 2014/2015 Trivalent Influenza Vaccine (CSL TIV-1), and a Trivalent Influenza Vaccine Containing the Alternate B Strain (CSL TIV-2), in Adults Aged 18 Years and Above.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and a trivalent influenza vaccine containing the alternate B strain (bioCSL TIV-2), in healthy adult volunteers aged 18 years and above.
Study identification
- NCT ID
- NCT02214225
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 3,484 participants
Conditions and interventions
Conditions
Interventions
- Quadrivalent Influenza Vaccine (QIV) Biological
- Trivalent Influenza Vaccine (TIV-1) Biological
- Trivalent Influenza Vaccine (TIV-2) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2014 (Type not available)
- Primary completion
- Nov 2014 (Actual)
- Completion
- Apr 2015 (Actual)
- Last update posted
- Mar 13, 2017
2014 – 2015
United States locations
- U.S. sites
- 33
- U.S. states
- 22
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 296 | Huntsville | Alabama | 35802 | — |
| Site 286 | Los Angeles | California | 90036 | — |
| Site 315 | San Diego | California | 92108 | — |
| Site 301 | Milford | Connecticut | 06460 | — |
| Site 297 | Jacksonville | Florida | 32207 | — |
| Site 293 | Melbourne | Florida | 32935 | — |
| Site 292 | Savannah | Georgia | 31406 | — |
| Site 289 | Meridian | Idaho | 83642 | — |
| Site 294 | Peoria | Illinois | 61614 | — |
| Site 295 | Mishawaka | Indiana | 46545 | — |
| Site 317 | Witchita | Kansas | 67207 | — |
| Site 291 | Rockville | Maryland | 20850 | — |
| Site 310 | Methuen | Massachusetts | 01844 | — |
| Site 287 | St Louis | Missouri | 63141 | — |
| Site 316 | Bellevue | Nebraska | 68005 | — |
| Site 298 | Las Vegas | Nevada | 89104 | — |
| Site 285 | Binghamton | New York | 13901 | — |
| Site 313 | Rochester | New York | 14642 | — |
| Site 302 | Charlotte | North Carolina | 28209 | — |
| Site 306 | Raleigh | North Carolina | 27609 | — |
| Site 309 | Wilmington | North Carolina | 28401 | — |
| Site 305 | Winston-Salem | North Carolina | 27103 | — |
| Site 299 | Oklahoma City | Oklahoma | 73112 | — |
| Site 307 | Mt. Pleasant | South Carolina | 29464 | — |
| Site 308 | Bristol | Tennessee | 37620 | — |
| Site 311 | Jefferson City | Tennessee | 37760 | — |
| Site 312 | Knoxville | Tennessee | 37912 | — |
| Site 304 | Knoxville | Tennessee | 37938 | — |
| Site 283 | Austin | Texas | 78705 | — |
| Site 282 | Forth Worth | Texas | 76135 | — |
| Site 288 | San Angelo | Texas | 76904 | — |
| Site 300 | Salt Lake City | Utah | 84124 | — |
| Site 303 | Charlottesville | Virginia | 22911 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02214225, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 13, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02214225 live on ClinicalTrials.gov.